Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2012

01-06-2012 | Original Article

Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis

Authors: Min Ji Shin, Sang Heon Song, Ihm Soo Kwak, Soo Bong Lee, Dong Won Lee, Eun Young Seong, Il Young Kim, Harin Rhee, Naria Lee

Published in: Clinical and Experimental Nephrology | Issue 3/2012

Login to get access

Abstract

Background

There has been no study to investigate whether cystatin C could predict cardiovascular events in incident dialysis patients. We aimed to delineate the role of serum cystatin C and cystatin C-based estimated glomerular filtration rate (eGFRcysC) for prediction of cardiovascular events.

Methods

This study included 66 end-stage renal disease patients who survived for >3 months after the start of dialysis, and serum cystain C levels were measured at the point of dialysis initiation.

Results

Serum cystatin C was correlated with blood urea nitrogen (r = 0.537, p < 0.001), serum creatinine (r = 0.480, p < 0.001) and smoking (r = 0.284, p = 0.021). Cystatin C was inversely correlated with age (r = −0.316, p = 0.01) and eGFRCr by modification of diet in renal disease (r = −0.533, p < 0.001). Kaplan–Meier analysis for cardiovascular events revealed that patients in the group with lower cystatin C levels (<4.14 mg/L) had a better event-free survival rate than patients in the group with higher cystatin C levels (≥4.14 mg/L) (p = 0.039). In univariate analysis, cystatin C (hazard ratio (HR) 2.62, p = 0.011) and eGFRcysC (HR 0.64, p = 0.004) were significant factors for the prediction of cardiovascular events. After multivariate adjustment, serum cystatin C and eGFRcysC were independent determinants of cardiovascular events (HR 3.952, p = 0.001 and HR 0.640, p = 0.004, respectively).

Conclusion

Serum cystatin C might be an independent marker of cardiovascular events in incident dialysis patients. Furthermore, eGFRcysC based on measured serum cystatin C could have a new role in predicting cardiovascular events beyond the estimation of true GFR.
Literature
1.
go back to reference Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis. 1998;32:S5–13.PubMedCrossRef Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis. 1998;32:S5–13.PubMedCrossRef
2.
go back to reference Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10–5.PubMedCrossRef Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10–5.PubMedCrossRef
3.
go back to reference Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–41.PubMedCrossRef Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–41.PubMedCrossRef
4.
go back to reference Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function. Circulation. 2002;106:2085–90.PubMedCrossRef Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function. Circulation. 2002;106:2085–90.PubMedCrossRef
5.
go back to reference Konings CJ, Hermans M, Kooman JP, Meinders JM, Hoeks AP, van der Sande FM, et al. Arterial stiffness and renal replacement therapy. Perit Dial Int. 2004;24:318–22.PubMed Konings CJ, Hermans M, Kooman JP, Meinders JM, Hoeks AP, van der Sande FM, et al. Arterial stiffness and renal replacement therapy. Perit Dial Int. 2004;24:318–22.PubMed
6.
go back to reference Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548–55.PubMedCrossRef Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548–55.PubMedCrossRef
7.
go back to reference Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003;63:1852–60.PubMedCrossRef Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003;63:1852–60.PubMedCrossRef
8.
go back to reference Song SH, Kwak IS, Kim YJ, Lee HS, Rhee H, Lee DW, et al. Serum cystatin C is related to pulse wave velocity even in subjects with normal serum creatinine. Hypertens Res. 2008;31:1895–902.PubMedCrossRef Song SH, Kwak IS, Kim YJ, Lee HS, Rhee H, Lee DW, et al. Serum cystatin C is related to pulse wave velocity even in subjects with normal serum creatinine. Hypertens Res. 2008;31:1895–902.PubMedCrossRef
9.
go back to reference Madero M, Wassel CL, Peralta CA, Najjar SS, Sutton-Tyrrell K, Fried L, et al. Cystatin C associates with arterial stiffness in older adults. J Am Soc Nephrol. 2009;20:1086–93.PubMedCrossRef Madero M, Wassel CL, Peralta CA, Najjar SS, Sutton-Tyrrell K, Fried L, et al. Cystatin C associates with arterial stiffness in older adults. J Am Soc Nephrol. 2009;20:1086–93.PubMedCrossRef
10.
go back to reference Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699–707.PubMed Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699–707.PubMed
11.
go back to reference Seronie-Vivien S, Delanaye P, Pieroni L, Mariat C, Froissart M, SFBC “Biology of renal function and renal failure” working group. Cystatin C: current position and future prospects. Clin Chem Lab Med. 2008;46:1664–86.PubMedCrossRef Seronie-Vivien S, Delanaye P, Pieroni L, Mariat C, Froissart M, SFBC “Biology of renal function and renal failure” working group. Cystatin C: current position and future prospects. Clin Chem Lab Med. 2008;46:1664–86.PubMedCrossRef
12.
go back to reference Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–60.PubMedCrossRef Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–60.PubMedCrossRef
13.
go back to reference Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45:268–71.PubMedCrossRef Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45:268–71.PubMedCrossRef
14.
go back to reference Astor BC, Levey AS, Stevens LA, Van Lente F, Selvin E, Coresh J. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol. 2009;20:2214–22.PubMedCrossRef Astor BC, Levey AS, Stevens LA, Van Lente F, Selvin E, Coresh J. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol. 2009;20:2214–22.PubMedCrossRef
15.
go back to reference Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med. 2007;147:19–27.PubMed Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med. 2007;147:19–27.PubMed
16.
go back to reference Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147–55.PubMedCrossRef Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147–55.PubMedCrossRef
17.
go back to reference Rule AD, Lieske JC. Cystatin C is more than GFR, and this may be a good thing. J Am Soc Nephrol. 2011;22:795–7.PubMedCrossRef Rule AD, Lieske JC. Cystatin C is more than GFR, and this may be a good thing. J Am Soc Nephrol. 2011;22:795–7.PubMedCrossRef
18.
go back to reference Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta. 2003;338:87–90.PubMedCrossRef Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta. 2003;338:87–90.PubMedCrossRef
19.
go back to reference Risch L, Herklotz R, Blumberg AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem. 2001;47:2055–9.PubMed Risch L, Herklotz R, Blumberg AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem. 2001;47:2055–9.PubMed
20.
go back to reference Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, et al. Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the national kidney disease education program. Clin Chem. 2006;52:5–18.PubMedCrossRef Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, et al. Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the national kidney disease education program. Clin Chem. 2006;52:5–18.PubMedCrossRef
21.
go back to reference Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406.PubMedCrossRef Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406.PubMedCrossRef
22.
go back to reference Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–46.PubMed Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–46.PubMed
23.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39:S1–266.CrossRef National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39:S1–266.CrossRef
24.
go back to reference Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.PubMedCrossRef Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.PubMedCrossRef
25.
go back to reference Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–21.PubMedCrossRef Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–21.PubMedCrossRef
26.
go back to reference Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008;51:385–94.PubMedCrossRef Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008;51:385–94.PubMedCrossRef
27.
go back to reference Odden MC, Tager IB, Gansevoort RT, Bakker SJ, Katz R, Fried LF, et al. Age and cystatin C in healthy adults: a collaborative study. Nephrol Dial Transplant. 2010;25:463–9.PubMedCrossRef Odden MC, Tager IB, Gansevoort RT, Bakker SJ, Katz R, Fried LF, et al. Age and cystatin C in healthy adults: a collaborative study. Nephrol Dial Transplant. 2010;25:463–9.PubMedCrossRef
28.
go back to reference Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant. 2007;22:1087–92.PubMedCrossRef Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant. 2007;22:1087–92.PubMedCrossRef
29.
go back to reference Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol. 2010;14:584–8.PubMedCrossRef Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol. 2010;14:584–8.PubMedCrossRef
30.
go back to reference Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–60.PubMedCrossRef Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–60.PubMedCrossRef
31.
go back to reference Yashiro M, Kamata T, Segawa H, Kadoya Y, Murakami T, Muso E. Comparisons of cystatin C with creatinine for evaluation of renal function in chronic kidney disease. Clin Exp Nephrol. 2009;13:598–604.PubMedCrossRef Yashiro M, Kamata T, Segawa H, Kadoya Y, Murakami T, Muso E. Comparisons of cystatin C with creatinine for evaluation of renal function in chronic kidney disease. Clin Exp Nephrol. 2009;13:598–604.PubMedCrossRef
32.
go back to reference Muntner P, Winston J, Uribarri J, Mann D, Fox CS. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med. 2008;121:341–8.PubMedCrossRef Muntner P, Winston J, Uribarri J, Mann D, Fox CS. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med. 2008;121:341–8.PubMedCrossRef
33.
go back to reference Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis. 2006;48:712–9.PubMedCrossRef Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis. 2006;48:712–9.PubMedCrossRef
34.
go back to reference Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Chinese eGFR Investigation Collaboration, et al. Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int. 2007;72:1535–42.PubMedCrossRef Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Chinese eGFR Investigation Collaboration, et al. Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int. 2007;72:1535–42.PubMedCrossRef
35.
go back to reference Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147–55.PubMedCrossRef Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147–55.PubMedCrossRef
36.
37.
go back to reference Mathisen UD, Melsom T, Ingebretsen OC, Jenssen T, Njølstad I, Solbu MD, et al. Estimated GFR associates with cardiovascular risk factors independently of measured GFR. J Am Soc Nephrol. 2011;22:927–37.PubMedCrossRef Mathisen UD, Melsom T, Ingebretsen OC, Jenssen T, Njølstad I, Solbu MD, et al. Estimated GFR associates with cardiovascular risk factors independently of measured GFR. J Am Soc Nephrol. 2011;22:927–37.PubMedCrossRef
38.
go back to reference Bengtsson E, To F, Håkansson K, Grubb A, Brånén L, Nilsson J, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2151–6.PubMedCrossRef Bengtsson E, To F, Håkansson K, Grubb A, Brånén L, Nilsson J, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2151–6.PubMedCrossRef
39.
go back to reference Lafarge JC, Naour N, Clément K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie. 2010;92:1580–6.PubMedCrossRef Lafarge JC, Naour N, Clément K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie. 2010;92:1580–6.PubMedCrossRef
40.
go back to reference Imai A, Komatsu S, Ohara T, et al. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. Atherosclerosis. 2011;218:350–5.PubMedCrossRef Imai A, Komatsu S, Ohara T, et al. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. Atherosclerosis. 2011;218:350–5.PubMedCrossRef
41.
go back to reference Maahs DM, Ogden LG, Kretowski A, et al. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes. 2007;56:5774–9.CrossRef Maahs DM, Ogden LG, Kretowski A, et al. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes. 2007;56:5774–9.CrossRef
42.
go back to reference Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321–7.PubMedCrossRef Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321–7.PubMedCrossRef
43.
go back to reference Luc G, Bard JM, Lesueur C, et al. Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis. 2006;185:375–80.PubMedCrossRef Luc G, Bard JM, Lesueur C, et al. Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis. 2006;185:375–80.PubMedCrossRef
44.
go back to reference Wang J, Sim AS, Wang XL, et al. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis. 2008;197:853–9.PubMedCrossRef Wang J, Sim AS, Wang XL, et al. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis. 2008;197:853–9.PubMedCrossRef
45.
go back to reference Jernberg T, Lindahl B, James S, et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342–8.PubMedCrossRef Jernberg T, Lindahl B, James S, et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342–8.PubMedCrossRef
46.
go back to reference Bassand JP, Hamm CW, Ardissino D, Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–660.PubMedCrossRef Bassand JP, Hamm CW, Ardissino D, Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–660.PubMedCrossRef
47.
go back to reference Samouilidou EC, Grapsa E. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis. Ren Fail. 2008;30:711–5.PubMedCrossRef Samouilidou EC, Grapsa E. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis. Ren Fail. 2008;30:711–5.PubMedCrossRef
48.
go back to reference Koc M, Batur MK, Karaarslan O, Abali G. Clinical utility of serum cystatin C in predicting coronary artery disease. Cardiol J. 2010;17:374–80.PubMed Koc M, Batur MK, Karaarslan O, Abali G. Clinical utility of serum cystatin C in predicting coronary artery disease. Cardiol J. 2010;17:374–80.PubMed
50.
go back to reference Ferraro S, Marano G, Biganzoli EM, Boracchi P, Bongo AS. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med. 2011;49:1397–404.PubMedCrossRef Ferraro S, Marano G, Biganzoli EM, Boracchi P, Bongo AS. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med. 2011;49:1397–404.PubMedCrossRef
Metadata
Title
Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis
Authors
Min Ji Shin
Sang Heon Song
Ihm Soo Kwak
Soo Bong Lee
Dong Won Lee
Eun Young Seong
Il Young Kim
Harin Rhee
Naria Lee
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0583-1

Other articles of this Issue 3/2012

Clinical and Experimental Nephrology 3/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.